ArticleCell reports2018
A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-κB.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 70 citations in OpenAlex.
- Patient-derived ependymoma and medulloblastoma tumoroids: generation, biobanking and drug screening.Nature protocols · 2026Review
- Article
- A systems approach identifies MERTK as a therapeutic vulnerability in ZFTA-RELA-driven ependymomas.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Integrated transcriptomic landscape of medulloblastoma and ependymoma reveals novel tumor subtype-specific biology.Neuro-oncology · 2026Article
- Synthetic ZFTA fusions pinpoint disordered protein domain acquisition as a mechanism of brain tumorigenesis.Nature cell biology · 2025Article
- Integrated transcriptomic landscape of medulloblastoma and ependymoma reveals novel tumor subtype-specific biology.bioRxiv : the preprint server for biology · 2025Article
- RNA polymerase II at histone genes predicts outcome in human cancer.Science (New York, N.Y.) · 2025Article
- RNA Polymerase II hypertranscription at histone genes in cancer FFPE samples.bioRxiv : the preprint server for biology · 2024Article
- ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse models.Cell reports · 2024Article
- Article
- Review
- Epigenomic analysis of formalin-fixed paraffin-embedded samples by CUT&Tag.Nature communications · 2023Article
- Identification of HDAC4 as a potential therapeutic target and prognostic biomarker for ZFTA-fused ependymomas.Cancer gene therapy · 2023Article
- Activation of Hedgehog signaling by the oncogenic RELA fusion reveals a primary cilia-dependent vulnerability in supratentorial ependymoma.Neuro-oncology · 2023Article
- Article
- Epigenetic Alterations of Repeated Relapses in Patient-matched Childhood Ependymomas.Nature communications · 2022Article
- Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma.Brain sciences · 2022Article
- Both YAP1-MAML2 and constitutively active YAP1 drive the formation of tumors that resemble NF2 mutant meningiomas in mice.Genes & development · 2022Article
- The biology of ependymomas and emerging novel therapies.Nature reviews. Cancer · 2022Review
- Ependymoma associated protein Zfta is expressed in immature ependymal cells but is not essential for ependymal development in mice.Scientific reports · 2022Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 9 institutions in 3 countries.
Tatsuya OzawaDivision of Human Biology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA; Seattle Tumor Translational Research (STTR), Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA; Alvord Brain Tumor Center, University of Washington, Seattle, WA 98109, USA; Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
Sonali AroraDivision of Human Biology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA.
Frank SzulzewskyDivision of Human Biology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA.
Gordana Juric-SekharDepartment of Pathology, University of Washington, Seattle, WA 98104, USA.
Yoshiteru MiyajimaDepartment of Neurosurgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.
Hamid BolouriDivision of Human Biology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA.
Yoshie YasuiDepartment of Neurosurgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.
Jason BarberDepartment of Neurosurgery, University of Washington, Seattle, WA 98109, USA.
Robert KuppCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
James DaltonDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Terreia S JonesUniversity of Tennessee Health Science Center, Department of Clinical Pharmacy, Memphis, TN 39103, USA.
Mitsutoshi NakadaDepartment of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa 920-8641, Japan.
Toshihiro KumabeDepartment of Neurosurgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.
David W EllisonDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Richard J GilbertsonCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK. Electronic address: richard.gilbertson@cruk.cam.ac.uk.
Eric C HollandDivision of Human Biology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA; Seattle Tumor Translational Research (STTR), Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA; Alvord Brain Tumor Center, University of Washington, Seattle, WA 98109, USA; Department of Neurosurgery, University of Washington, Seattle, WA 98109, USA. Electronic address: eholland@fredhutch.org.
University of Washington · USKitasato University · JPAllen Institute for Brain Science · USSt. Jude Children's Research Hospital · USCancer Research UK · GBFred Hutch Cancer Center · USKanazawa University · JPUniversity of Cambridge · GBUniversity of Tennessee Health Science Center · US
Funding
The DNA Damage Response and Tumorigenesis in the BrainP01CA096832 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI BAKER, SUZANNE J. · 2003 to 2025
$38.0MThe Cell-Of-Origin of Human CancersU54CA143798 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI MICHOR, FRANZISKA · 2009 to 2014
$11.2MProject 3: Single Cell Measures of Intratumor Diversity for Optimal Breast Cancer TherapyU54CA193461 · NCI · DANA-FARBER CANCER INST · PI POLYAK, KORNELIA · 2015 to 2020
$11.2MUsing mouse models to probe the relationship of oncogenesis to development and oU01CA105492 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI HOLLAND, ERIC C. · 2004 to 2013
$5.8MThe Proneural Perivascular Niche and Therapeutic ResponseU54CA163167 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI HUSE, JASON · 2011 to 2015
$4.6MP3IK Signaling and Biology of Therapeutic Response in Brain and Prostate TumorsU01CA141502 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI HOLLAND, ERIC C. · 2009 to 2013
$4.2MThe Role of Signaling Pathways in Brain Tumors in MiceR01CA100688 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI HOLLAND, ERIC C. · 2003 to 2013
$3.8MAn Investigation of Radial Glia as the Source of Ependymoma Stem CellsR01CA129541 · NCI · UNIVERSITY OF CAMBRIDGE · PI GILBERTSON, RICHARD · 2007 to 2016
$3.0MUsing genetically engineered mouse models of brain tumors to develop therapeutic nanoparticles & biomaterialsR01CA195718 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HOLLAND, ERIC C., HOUGHTON, A MCGARRY · 2016 to 2018
$1.9MPhysical Science Oncology Center Training ProgramT32CA157323 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI HOLLAND, ERIC C., MICHOR, FRANZISKA · 2012 to 2012
$115kCancer Research UK 22492Cancer Research UK 26398NCI NIH HHS P01 CA096832NCI NIH HHS R01 CA100688NCI NIH HHS R01 CA129541NCI NIH HHS R01 CA195718NCI NIH HHS T32 CA157323NCI NIH HHS U01 CA105492NCI NIH HHS U01 CA141502NCI NIH HHS U54 CA143798NCI NIH HHS U54 CA163167NCI NIH HHS U54 CA193461
Abstract
The majority of supratentorial ependymomas (ST-ependymomas) have few mutations but frequently display chromothripsis of chromosome 11q that generates a fusion between C11orf95 and RELA (RELA
Indexed as
AnimalsBrain NeoplasmsCell Transformation, NeoplasticDisease Models, AnimalDNA-Binding ProteinsEpendymomaMiceNeural Stem CellsOncogene FusionPrincipal Component AnalysisSignal TransductionTranscription Factor RelATranscriptome2700081o15rik protein, mouseDNA-Binding ProteinsTranscription Factor RelAC11orf95ependymomafusion genemouse modelNF-κB signalingRCAS/tv-a systemRELA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.